SCHEMBL6887459

SCHEMBL6887459

O=c1c2cc(N3CCN4CCC3CC4)ccc2nc(-c2ccccc2F)n1CC1(CO)CCC1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.40
CHRNA1 P02708 2/20 0.40
CHRNB2 P17787 2/20 0.40
CHRNB4 P30926 2/20 0.40
CHRNA3 P32297 2/20 0.40
CHRNA4 P43681 2/20 0.40
HTR3A P46098 2/20 0.40
GHSR Q92847 2/20 0.37
KCNH2 Q12809 2/20 0.37
CYP2D6 P10635 2/20 0.35
CASR P41180 4/20 0.35
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
HTR2C P28335 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887505 0.90 CHRNA7 (0.40) CHRNA7ALDH1A1
SCHEMBL6887969 0.87 AVPR1B (0.38) CHRNA7CHRNA1CHRNB2CHRNB4CHRNA3
SCHEMBL6886382 0.86 CHRNA7 (0.44) CHRNA7CHRNA1CHRNB2CHRNB4CHRNA3
SCHEMBL6887510 0.85 CHRNA7 (0.38) CHRNA7MEN1ALDH1A1KMT2A
SCHEMBL6887857 0.85 CHRNA7 (0.37) CHRNA7CHRNA1CHRNB2CHRNB4CHRNA3
SCHEMBL6887358 0.84 AVPR1A (0.41)
SCHEMBL6891194 0.84 CHRNA7 (0.43) CHRNA7CHRNA1CHRNB2CHRNB4CHRNA3
SCHEMBL6890362 0.83 CHRNA7 (0.39) CHRNA7CHRNA1CHRNB2CHRNB4CHRNA3
SCHEMBL11920584 0.82 CHRNA7 (0.35) CHRNA7CHRNA1CHRNB2CHRNB4CHRNA3
SCHEMBL1669146 0.82 CHRNA7 (0.35) CHRNA7CYP2D6MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
WO-2011045258-A1 CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR N.V. ORGANON (NL) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208796-A1 HETEROCYCLIC DERIVATIVES CHRNA5, CHRM5, CHRNA7 CHRNA7 3/4885CHRNA1 6/4885CHRNB2 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.